DUPLICATE

Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: OC01620K	APPLICATION NO.: 10/654,163
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: Timothy J. Guzi *et al.*	
(Use several sheets if necessary)	FILING DATE: 09/03/2003	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	AL	DE 102 23 917 A1	12/11/2003	Germany				
	AM	EP 1 199 306 A1	04/24/2002	Europe				
	AN	EP 0 714 898 A1	06/05/1996	Europe				
	AO	WO 02/50079 A1	06/27/2002	WIPO				
	AP	WP 03/091256 A1	11/06/2003	WIPO				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AQ	Adrian M. Senderowicz *et al.*, "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators", *J. Natl. Cancer Inst.*, 92(5):376-387 (March 1, 2000).
	AR	Teruki Honma *et al.*, "Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New *de Novo* Design Strategy and Library Design", *J. Med. Chem.*, 44: 4615-4627 (2001).
	AS	Translation of WO 03/91256, *A Rising Sun Communications Ltd. Translation Product*, (1-62).
	AT	
	AU	
	AV	

EXAMINER	DATE CONSIDERED
	6/14/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO- U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:	APPLICATION NO.:
OC01620K	10/654,163
APPLICANT: Tim thy J. Guzi t al.	
FILING DATE: 09/03/2003	GROUP: 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA	US 5,571,813	11/05/1996	Rühter *et al.*			
	AB	US 5,602,136	02/11/1997	Rühter *et al.*			
	AC	US 5,602,137	02/11/1997	Rühter *et al.*			
	AD	US 5,688,949	11/18/1997	Inoue *et al.*			
	AE	US 5,707,997	01/13/1998	Shoji *et al.*			
	AF	US 5,919,815	07/06/1999	Bradley *et al.*			
	AG	US 6,040,321	03/21/2000	Kim *et al.*			
	AH	US 6,191,131	02/20/2001	He *et al.*			
	AI	US 6,262,096	07/17/2001	Kim *et al.*			
	AJ	US 6,413,974	07/02/2002	Dumont *et al.*			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	AK	EP 0 628 559	04/03/2002	Europe				
	AL	EP 1 334 973	08/13/2003	Europe				
	AM	WO 02/40485	05/23/2002	PCT				
	AN	WO 02/50079	06/27/2002	PCT				
	AO	WO 95/35298	12/28/1995	PCT				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AP	Vesely *et al.*, "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", *Eur. J. Biochem* (1994), 224: 771-786.
	AQ	Kim *et al.*, "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", *Journal of Medical Chemistry*, Page EST:22.3, A-W.
	AR	Mettey *et al.*, "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structur in Complex with CDK2, Enzyme Selectivity, and Cellular Effects", *J. Med. Chem.* (2003), 46(2): 222-236.
	AS	Novinson *et al.*, "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-a]pyrimidines", *J. Med. Chem.* (1977), 20(2): 296-299.
	AT	Senderowicz *et al.*, "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", *Journal of Clinical Oncology* (September 1998), 16(9): 2986-2999.
	AU	Meijer *et al.*, "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", *Eur. J. Biochem.* (1997), 243:527-536.
	AV	Bible *et al.*, "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", *Cancer Research* (August 15, 1997), 57: 3375-3380.
	AW	Shiota *et al.*, "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-a]pyrimidine Derivatives", *Chem. Pharm. Bull.* (1999), 47(7): 928-938.
	AX	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-a]pyrimidines.", *Chem. Pharm. Bull* (1962), 10: 620-626.

EXAMINER	DATE CONSIDERED
Tom McKay	6/15/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.